- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.P1213
Amino-acid Sequence
CAS No.
Selleck's gp91ds-tat Has Been Cited by 1 Publication
| Storage (From the date of receipt) | 3 years-20°C powder | ||
|
In vitro |
Water : 49 mg/mL |
Molecular Weight Calculator |
|
In vivo Add solvents to the product individually and in order. |
In vivo Formulation Calculator |
||||
| Description | gp91ds-tat, a peptide inhibitor for NADPH oxidase assembly, is composed of gp91phox sequence linked to the human immunodeficiency virus-tat peptide. The tat sequence facilitates the entry of this peptide into cells. |
|---|---|
| Targets/IC50/Ki |
NADPH oxidase
|
In vitro |
||||
| In vitro | Gp91ds-tat, an inhibitor of NOX (NADPH oxidase) 2, can prevented high extracellular glucose (Hi-Glu)/Thiamet G (ThmG)-induced ROS generation. |
|||
|---|---|---|---|---|
In Vivo |
||
| In vivo |
Gp91ds-tat can attenuate cerebral I/R injury in a rat model of middle cerebral artery occlusion (MCAO) through reducing ROS levels, inhibiting neuronal apoptosis and degeneration, and alleviating BBB damage. |
|
|---|---|---|
| Animal Research | Animal Models | middle cerebral artery occlusion (MCAO) model rats |
| Dosages | 100 ng/kg | |
| Administration | infused into the ventricle | |
References |
|
| Molecular Formula | C109H202N52O25S1 |
|---|---|
| Molecular Weight | 2673.3 |
| Appearance | White Powder |
| Peptide Content (by %N) | ≥80% |
| Single Impurity (by HPLC) | ≤1.0% |
| Assay (By Anhydrous, Acetic Acid-free) | 95.0~105.0% |
| MS | Consistent |
| Packing | plastic vial(dedicated for peptide packing) or glass vial, quantity according to customer's detail requirement. |
| Storage (From the date of receipt) |
3 years-20°C powder |
| Shipping | Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.) |